MXCT
$0.80
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Recent News
MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery
MaxCyte Inc. (NASDAQ:MXCT) is one of the best penny stocks under $1 to buy right now. On February 24, MaxCyte launched the ExPERT DTx, which is a high-throughput 96-well electroporation platform designed to accelerate research and drug discovery. This modular system allows labs to transfect primary cells and various cell lines with minimal cellular stress, […]
MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges
MaxCyte Inc (MXCT) navigates a tough market with strategic partnerships and restructuring, while maintaining a strong cash position for future growth.
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. As part of this agreement, Adicet gets non-exclusive rights to […]